Cancer Trials Need to Recruit Overlooked Patients, FDA Says (1)

Cancer patients who have typically been left out of clinical trials will have an easier time accessing experimental, cutting edge therapies under a new policy from the FDA.

The Food and Drug Administration Friday issued a set of four final guidance documents on how to include in cancer therapy trials patients with HIV, hepatitis B, or hepatitis C; patients whose cancers have spread to the brain, which is common for late-stage lung cancers; and patients with organ dysfunctions.

They also lay out how to include children or when to include an adolescent in an adult clinical trial. The agency aims ...